



# Novogen Limited

Presentation to Australia Biotech Invest Annual Conference

Dr James Garner  
Chief Executive Officer  
[james.garner@novogen.com](mailto:james.garner@novogen.com)

Melbourne, VIC  
26<sup>th</sup> October 2016

# Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

# Novogen is a biotech company dedicated to driving sustainable, long-term growth in shareholder value

## Focus on unmet medical need

Pipeline of novel therapies, targeting oncology patients poorly served by existing treatment options

## Financially sound

Listed on ASX and NASDAQ, with cash runway sufficient to drive existing pipeline for at least two years

## Clinical stage

Lead molecule entering phase I in Q4 2016, with substantial flow of value-driving milestones over 12-18 months

## Strong management and Board


Lean team of internationally-experienced pharma executives, overseen by seasoned Board

# Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations




<b>Market Capitalisation</b>	AU\$ 41 million
<b>Listing</b>	ASX: NRT NASDAQ: NVGN (1:25 ratio)
<b>Average Daily Volume</b>	ASX: ~570,000 /day NASDAQ: ~50,000 ADRs /day
<b>Shares on Issue</b>	450 million (40% US, 60% Australia)
<b>Outstanding Options / Warrants</b>	74 million
<b>Cash at Bank</b> US\$ 25 million	

# Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations



# Novogen is configured for efficient and effective drug development



- Rationalisation of portfolio to focus on three most advanced oncology opportunities; deprioritization of early stage rare diseases program
- Addition of internationally-experienced pharma executives to team
- Establishment of Scientific Advisory Board
- Development of rigorous GxP quality systems
- Rationalisation of corporate structure and governance

# Novogen has a strong management team with international experience in big pharma



**Dr James Garner**  
Chief Executive Officer & Managing Director

*Physician / MBA; Extensive pharma drug development experience*



**Dr David Brown**  
Chief Scientific Officer

*Twenty years of drug discovery and development experience*



**Dr Gordon Hirsch**  
Chief Medical Officer

*Physician / MBA; Twenty years of pharmaceutical industry experience*



**Dr Peng Leong**  
Chief Business Officer

*Eighteen years of business development and investment banking experience*



**Dr Andrew Heaton**  
VP, Drug Discovery

*Twenty years of medicinal chemistry experience*




**Cristyn Humphreys**  
Chief Financial Officer

*Chartered accountant with twenty years of experience in corporate roles*

# Novogen's pipeline includes three molecules, with two entering the clinic over the next nine months

ATM Platform	First-in-class program targeting cancer-specific tropomyosin isoform in cytoskeletal microfilaments of cancer cells, leading to apoptosis
SBP Platform	First-in-class program based on earlier clinically-validated isoflavone chemotype (e.g. phenoxidiol, MEI Pharma), but with distinct IP space and greater preclinical activity





# Novogen anticipates a rich news flow of value-driving events over the next 12-18 months

Key Milestones		
1Q 2016	Granting of patent for SBP technology	✓
2Q 2016	Granting of patent for ATM technology	✓
3Q 2016	Submission of IND for Cantrixil	✓
4Q 2016	Start of phase I trial for Cantrixil	
2017	Submission of IND for Anisina	
2017	Start of phase I trial for Anisina	



